25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TRAW (Traws Pharma Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Traws Pharma Inc together

I guess you are interested in Traws Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Traws Pharma Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Traws Pharma Inc’s Price Targets

I'm going to help you getting a better view of Traws Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Traws Pharma Inc

I send you an email if I find something interesting about Traws Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Traws Pharma Inc (30 sec.)










1.2. What can you expect buying and holding a share of Traws Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.17
Expected worth in 1 year
$17.28
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$16.11
Return On Investment
715.9%

For what price can you sell your share?

Current Price per Share
$2.25
Expected price per share
$1.26 - $2.63
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Traws Pharma Inc (5 min.)




Live pricePrice per Share (EOD)
$2.25
Intrinsic Value Per Share
$-79,271.69 - $-28,591.22
Total Value Per Share
$-79,270.52 - $-28,590.05

2.2. Growth of Traws Pharma Inc (5 min.)




Is Traws Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$8.2m-$18.5m$13.7m283.1%

How much money is Traws Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money$21.9m-$34.2m$56.1m256.4%
Net Profit Margin39,464.4%-60,181.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Traws Pharma Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Traws Pharma Inc?

Welcome investor! Traws Pharma Inc's management wants to use your money to grow the business. In return you get a share of Traws Pharma Inc.

First you should know what it really means to hold a share of Traws Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Traws Pharma Inc is $2.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Traws Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Traws Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.17. Based on the TTM, the Book Value Change Per Share is $4.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-4.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Traws Pharma Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.13-5.8%3.09137.3%-4.75-211.2%-0.76-33.7%-0.72-31.8%-0.72-31.8%
Usd Book Value Change Per Share0.3415.0%4.03179.0%-4.40-195.7%-0.36-15.8%-0.05-2.3%0.010.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.3415.0%4.03179.0%-4.40-195.7%-0.36-15.8%-0.05-2.3%0.010.6%
Usd Price Per Share1.48-4.64-0.73-2.07-2.16-2.10-
Price to Earnings Ratio-2.86--0.90--0.39--0.57--0.74--0.74-
Price-to-Total Gains Ratio4.38-0.77-0.32-0.11--1.04--2.09-
Price to Book Ratio1.27--4.60-0.74--1.17--0.51-0.72-
Price-to-Total Gains Ratio4.38-0.77-0.32-0.11--1.04--2.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.25
Number of shares444
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share4.03-0.05
Usd Total Gains Per Share4.03-0.05
Gains per Quarter (444 shares)1,787.95-23.17
Gains per Year (444 shares)7,151.82-92.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10715271420-93-103
2014304142940-185-196
3021455214460-278-289
4028607285980-371-382
5035759357500-463-475
6042911429020-556-568
7050063500540-649-661
8057215572060-741-754
9064366643580-834-847
10071518715100-927-940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%3.037.00.07.5%3.051.00.05.6%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%7.013.00.035.0%14.026.00.035.0%16.035.03.029.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.054.00.0%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%7.013.00.035.0%14.026.00.035.0%16.035.03.029.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Traws Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3384.027-92%-4.403+1403%-0.357+205%-0.052+115%0.013+2491%
Book Value Per Share--1.170-0.691+159%-2.881+346%-0.191+116%1.762-34%1.169+0%
Current Ratio--2.0911.784+17%2.265-8%2.864-27%4.262-51%3.201-35%
Debt To Asset Ratio--0.4711.163-59%2.077-77%1.184-60%0.831-43%0.936-50%
Debt To Equity Ratio--0.8910.767+16%1.002-11%0.744+20%0.688+29%1.204-26%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--16175466.92024773342.615-35%-12644692.649+178%15153217.027+7%28444906.520-43%22651695.007-29%
Eps---0.1303.090-104%-4.752+3569%-0.758+485%-0.716+453%-0.716+452%
Ev To Ebitda Ratio---4.424-1.372-69%-0.667-85%-1.215-73%-1.925-57%-1.391-69%
Ev To Sales Ratio--1.48091.827-98%-54.757+3801%61.532-98%122.040-99%77.911-98%
Free Cash Flow Per Share---1615.351-404.575-75%-0.717-100%-135.265-92%-81.437-95%-41.101-97%
Free Cash Flow To Equity Per Share---1614.913-403.758-75%-0.221-100%-134.828-92%-80.760-95%-40.373-97%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---28591.218----------
Intrinsic Value_10Y_min---79271.694----------
Intrinsic Value_1Y_max---556.100----------
Intrinsic Value_1Y_min---1810.007----------
Intrinsic Value_3Y_max---3430.536----------
Intrinsic Value_3Y_min---10782.987----------
Intrinsic Value_5Y_max---8426.476----------
Intrinsic Value_5Y_min---25544.705----------
Market Cap15893615.250+34%10454466.92032827842.615-68%7743807.351+35%16293217.027-36%16209206.520-36%15335845.007-32%
Net Profit Margin---0.335394.644-100%-601.810+179654%-99.820+29715%-91.780+27314%-69.992+20806%
Operating Margin---0.335-76.581+22774%-603.051+180024%-257.308+76755%-186.270+55537%-117.418+34971%
Operating Ratio--1.457194.034-99%92.333-98%128.441-99%109.586-99%79.976-98%
Pb Ratio1.924+34%1.265-4.596+463%0.742+70%-1.174+193%-0.511+140%0.718+76%
Pe Ratio-4.343-52%-2.856-0.904-68%-0.391-86%-0.567-80%-0.740-74%-0.744-74%
Price Per Share2.250+34%1.4804.635-68%0.728+103%2.074-29%2.155-31%2.101-30%
Price To Free Cash Flow Ratio0.000-52%0.000-1.387+605626%-0.412+179688%-0.768+335112%-0.825+360238%-0.765+333899%
Price To Total Gains Ratio6.656+34%4.3780.773+466%0.321+1264%0.105+4067%-1.035+124%-2.085+148%
Quick Ratio--1.9591.639+20%2.080-6%2.721-28%4.138-53%3.083-36%
Return On Assets---0.0590.767-108%-1.806+2983%-0.394+572%-0.289+393%-0.334+470%
Return On Equity---0.1110.601-118%-0.387+249%0.002-5291%-0.107-4%-0.342+208%
Total Gains Per Share--0.3384.027-92%-4.403+1403%-0.357+205%-0.052+115%0.013+2491%
Usd Book Value--8262000.000-4850250.000+159%-18579000.000+325%811416.667+918%13741500.000-40%8909675.000-7%
Usd Book Value Change Per Share--0.3384.027-92%-4.403+1403%-0.357+205%-0.052+115%0.013+2491%
Usd Book Value Per Share--1.170-0.691+159%-2.881+346%-0.191+116%1.762-34%1.169+0%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--16175466.92024773342.615-35%-12644692.649+178%15153217.027+7%28444906.520-43%22651695.007-29%
Usd Eps---0.1303.090-104%-4.752+3569%-0.758+485%-0.716+453%-0.716+452%
Usd Free Cash Flow---11410563000.000-2857879000.000-75%-5797250.000-100%-955960166.667-92%-575537500.000-95%-290468375.000-97%
Usd Free Cash Flow Per Share---1615.351-404.575-75%-0.717-100%-135.265-92%-81.437-95%-41.101-97%
Usd Free Cash Flow To Equity Per Share---1614.913-403.758-75%-0.221-100%-134.828-92%-80.760-95%-40.373-97%
Usd Market Cap15893615.250+34%10454466.92032827842.615-68%7743807.351+35%16293217.027-36%16209206.520-36%15335845.007-32%
Usd Price Per Share2.250+34%1.4804.635-68%0.728+103%2.074-29%2.155-31%2.101-30%
Usd Profit---915000.00021905000.000-104%-34262250.000+3645%-5856000.000+540%-5362550.000+486%-5206374.975+469%
Usd Revenue--2733000.000725750.000+277%56500.000+4737%279583.333+878%190850.000+1332%622199.975+339%
Usd Total Gains Per Share--0.3384.027-92%-4.403+1403%-0.357+205%-0.052+115%0.013+2491%
 EOD+6 -2MRQTTM+12 -25YOY+26 -113Y+21 -165Y+16 -2110Y+20 -17

3.3 Fundamental Score

Let's check the fundamental score of Traws Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.343
Price to Book Ratio (EOD)Between0-11.924
Net Profit Margin (MRQ)Greater than0-0.335
Operating Margin (MRQ)Greater than0-0.335
Quick Ratio (MRQ)Greater than11.959
Current Ratio (MRQ)Greater than12.091
Debt to Asset Ratio (MRQ)Less than10.471
Debt to Equity Ratio (MRQ)Less than10.891
Return on Equity (MRQ)Greater than0.15-0.111
Return on Assets (MRQ)Greater than0.05-0.059
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Traws Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.411
Ma 20Greater thanMa 501.928
Ma 50Greater thanMa 1001.677
Ma 100Greater thanMa 2001.594
OpenGreater thanClose1.830
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Traws Pharma Inc

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Fundamental data was last updated by Penke on 2025-10-05 19:26:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Traws Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -33.5%Β means thatΒ $-0.33 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Traws Pharma Inc:

  • The MRQ is -33.5%. The company is making a huge loss. -2
  • The TTM is 39,464.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-33.5%TTM39,464.4%-39,497.9%
TTM39,464.4%YOY-60,181.0%+99,645.4%
TTM39,464.4%5Y-9,178.0%+48,642.5%
5Y-9,178.0%10Y-6,999.2%-2,178.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.5%-65.5%+32.0%
TTM39,464.4%-147.4%+39,611.8%
YOY-60,181.0%-189.7%-59,991.3%
3Y-9,982.0%-259.0%-9,723.0%
5Y-9,178.0%-337.1%-8,840.9%
10Y-6,999.2%-472.3%-6,526.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Traws Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • -5.9% Return on Assets means thatΒ Traws Pharma Inc generatedΒ $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Traws Pharma Inc:

  • The MRQ is -5.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 76.7%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ-5.9%TTM76.7%-82.5%
TTM76.7%YOY-180.6%+257.3%
TTM76.7%5Y-28.9%+105.5%
5Y-28.9%10Y-33.4%+4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.9%-11.9%+6.0%
TTM76.7%-11.9%+88.6%
YOY-180.6%-11.3%-169.3%
3Y-39.4%-12.0%-27.4%
5Y-28.9%-11.9%-17.0%
10Y-33.4%-14.0%-19.4%
4.3.1.3. Return on Equity

Shows how efficient Traws Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • -11.1% Return on Equity means Traws Pharma Inc generated $-0.11Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Traws Pharma Inc:

  • The MRQ is -11.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 60.1%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ-11.1%TTM60.1%-71.2%
TTM60.1%YOY-38.7%+98.8%
TTM60.1%5Y-10.7%+70.8%
5Y-10.7%10Y-34.2%+23.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.1%-14.1%+3.0%
TTM60.1%-14.7%+74.8%
YOY-38.7%-15.3%-23.4%
3Y0.2%-16.8%+17.0%
5Y-10.7%-17.4%+6.7%
10Y-34.2%-19.8%-14.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Traws Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Traws Pharma Inc is operatingΒ .

  • Measures how much profit Traws Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of -33.5%Β means the company generated $-0.33 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Traws Pharma Inc:

  • The MRQ is -33.5%. The company is operating very inefficient. -2
  • The TTM is -7,658.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-33.5%TTM-7,658.1%+7,624.6%
TTM-7,658.1%YOY-60,305.1%+52,647.0%
TTM-7,658.1%5Y-18,627.0%+10,968.9%
5Y-18,627.0%10Y-11,741.8%-6,885.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.5%-148.3%+114.8%
TTM-7,658.1%-255.8%-7,402.3%
YOY-60,305.1%-240.0%-60,065.1%
3Y-25,730.8%-245.6%-25,485.2%
5Y-18,627.0%-330.8%-18,296.2%
10Y-11,741.8%-487.4%-11,254.4%
4.3.2.2. Operating Ratio

Measures how efficient Traws Pharma Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.46 means that the operating costs are $1.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Traws Pharma Inc:

  • The MRQ is 1.457. The company is inefficient in keeping operating costs low. -1
  • The TTM is 194.034. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.457TTM194.034-192.576
TTM194.034YOY92.333+101.701
TTM194.0345Y109.586+84.448
5Y109.58610Y79.976+29.609
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4571.853-0.396
TTM194.0342.652+191.382
YOY92.3332.829+89.504
3Y128.4413.550+124.891
5Y109.5864.636+104.950
10Y79.9766.253+73.723
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Traws Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Traws Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.09Β means the company has $2.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Traws Pharma Inc:

  • The MRQ is 2.091. The company is able to pay all its short-term debts. +1
  • The TTM is 1.784. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.091TTM1.784+0.307
TTM1.784YOY2.265-0.481
TTM1.7845Y4.262-2.478
5Y4.26210Y3.201+1.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0913.448-1.357
TTM1.7843.644-1.860
YOY2.2654.060-1.795
3Y2.8644.461-1.597
5Y4.2625.731-1.469
10Y3.2016.128-2.927
4.4.3.2. Quick Ratio

Measures if Traws Pharma Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.96Β means the company can pay off $1.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Traws Pharma Inc:

  • The MRQ is 1.959. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.639. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.959TTM1.639+0.320
TTM1.639YOY2.080-0.441
TTM1.6395Y4.138-2.499
5Y4.13810Y3.083+1.056
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9592.764-0.805
TTM1.6393.124-1.485
YOY2.0803.845-1.765
3Y2.7214.322-1.601
5Y4.1385.680-1.542
10Y3.0836.522-3.439
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Traws Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Traws Pharma IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Traws Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.47Β means that Traws Pharma Inc assets areΒ financed with 47.1% credit (debt) and the remaining percentage (100% - 47.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Traws Pharma Inc:

  • The MRQ is 0.471. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 1.163. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ0.471TTM1.163-0.692
TTM1.163YOY2.077-0.914
TTM1.1635Y0.831+0.331
5Y0.83110Y0.936-0.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4710.341+0.130
TTM1.1630.361+0.802
YOY2.0770.331+1.746
3Y1.1840.343+0.841
5Y0.8310.350+0.481
10Y0.9360.381+0.555
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Traws Pharma Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 89.1% means that company has $0.89 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Traws Pharma Inc:

  • The MRQ is 0.891. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.767. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.891TTM0.767+0.124
TTM0.767YOY1.002-0.235
TTM0.7675Y0.688+0.079
5Y0.68810Y1.204-0.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8910.395+0.496
TTM0.7670.438+0.329
YOY1.0020.432+0.570
3Y0.7440.471+0.273
5Y0.6880.467+0.221
10Y1.2040.518+0.686
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Traws Pharma Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Traws Pharma Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -2.86 means the investor is paying $-2.86Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Traws Pharma Inc:

  • The EOD is -4.343. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.856. Based on the earnings, the company is expensive. -2
  • The TTM is -0.904. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.343MRQ-2.856-1.486
MRQ-2.856TTM-0.904-1.953
TTM-0.904YOY-0.391-0.513
TTM-0.9045Y-0.740-0.164
5Y-0.74010Y-0.744+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.343-2.738-1.605
MRQ-2.856-2.296-0.560
TTM-0.904-2.657+1.753
YOY-0.391-3.631+3.240
3Y-0.567-3.737+3.170
5Y-0.740-5.974+5.234
10Y-0.744-6.848+6.104
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Traws Pharma Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.387. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.0000.000
MRQ0.000TTM-1.387+1.387
TTM-1.387YOY-0.412-0.976
TTM-1.3875Y-0.825-0.562
5Y-0.82510Y-0.765-0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.422+3.422
MRQ0.000-2.906+2.906
TTM-1.387-3.631+2.244
YOY-0.412-4.296+3.884
3Y-0.768-5.238+4.470
5Y-0.825-8.367+7.542
10Y-0.765-9.706+8.941
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Traws Pharma Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.27 means the investor is paying $1.27Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Traws Pharma Inc:

  • The EOD is 1.924. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.265. Based on the equity, the company is underpriced. +1
  • The TTM is -4.596. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.924MRQ1.265+0.658
MRQ1.265TTM-4.596+5.861
TTM-4.596YOY0.742-5.338
TTM-4.5965Y-0.511-4.084
5Y-0.51110Y0.718-1.229
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9242.488-0.564
MRQ1.2652.047-0.782
TTM-4.5962.204-6.800
YOY0.7422.464-1.722
3Y-1.1742.632-3.806
5Y-0.5113.755-4.266
10Y0.7184.450-3.732
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Accumulated Other Comprehensive Income  -330-33-9-4223-19289



6.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets15,622
Total Liabilities7,360
Total Stockholder Equity8,262
 As reported
Total Liabilities 7,360
Total Stockholder Equity+ 8,262
Total Assets = 15,622

Assets

Total Assets15,622
Total Current Assets15,370
Long-term Assets252
Total Current Assets
Cash And Cash Equivalents 13,081
Net Receivables 1,323
Other Current Assets 966
Total Current Assets  (as reported)15,370
Total Current Assets  (calculated)15,370
+/-0
Long-term Assets
Property Plant Equipment 8
Long-term Assets Other 244
Long-term Assets  (as reported)252
Long-term Assets  (calculated)252
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,352
Long-term Liabilities8
Total Stockholder Equity8,262
Total Current Liabilities
Accounts payable 4,759
Other Current Liabilities 2,593
Total Current Liabilities  (as reported)7,352
Total Current Liabilities  (calculated)7,352
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)8
Long-term Liabilities  (calculated)0
+/- 8
Total Stockholder Equity
Common Stock71
Retained Earnings -628,579
Accumulated Other Comprehensive Income 9
Other Stockholders Equity 636,761
Total Stockholder Equity (as reported)8,262
Total Stockholder Equity (calculated)8,262
+/-0
Other
Capital Stock71
Cash and Short Term Investments 13,081
Common Stock Shares Outstanding 5,821
Liabilities and Stockholders Equity 15,622
Net Debt -13,081
Net Invested Capital 8,262
Net Working Capital 8,018
Property Plant and Equipment Gross 84



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
0
0
0
83,852
70,759
57,914
122,717
105,153
89,718
74,573
62,274
47,337
36,713
27,737
25,969
23,445
19,642
16,202
28,088
23,233
16,554
16,100
8,802
4,979
8,615
30,203
23,136
17,923
11,341
8,580
6,005
23,674
32,073
28,199
25,207
19,986
48,849
44,378
59,990
55,478
51,422
48,074
43,780
39,372
35,061
30,468
27,038
22,683
18,172
18,686
8,936
24,962
19,063
15,622
15,62219,06324,9628,93618,68618,17222,68327,03830,46835,06139,37243,78048,07451,42255,47859,99044,37848,84919,98625,20728,19932,07323,6746,0058,58011,34117,92323,13630,2038,6154,9798,80216,10016,55423,23328,08816,20219,64223,44525,96927,73736,71347,33762,27474,57389,718105,153122,71757,91470,75983,852000
   > Total Current Assets 
0
0
0
83,252
69,973
57,048
121,928
104,390
89,024
73,827
61,625
46,905
36,353
27,425
25,684
23,185
19,406
15,990
27,900
23,069
16,413
15,983
8,707
4,903
8,555
30,157
23,104
17,765
11,190
8,429
5,801
23,474
31,876
27,989
25,001
19,784
48,650
44,193
59,936
55,430
51,377
48,033
43,751
39,347
35,039
30,450
27,011
22,660
18,153
18,671
8,923
24,951
18,856
15,370
15,37018,85624,9518,92318,67118,15322,66027,01130,45035,03939,34743,75148,03351,37755,43059,93644,19348,65019,78425,00127,98931,87623,4745,8018,42911,19017,76523,10430,1578,5554,9038,70715,98316,41323,06927,90015,99019,40623,18525,68427,42536,35346,90561,62573,82789,024104,390121,92857,04869,97383,252000
       Cash And Cash Equivalents 
0
0
0
81,527
67,307
51,181
76,612
60,009
54,624
55,499
42,348
43,582
33,698
25,358
22,197
19,799
16,835
12,818
25,778
21,450
15,389
14,989
7,600
4,024
7,264
29,540
22,384
16,970
10,396
5,882
4,821
22,726
31,036
27,228
24,198
19,025
48,005
43,709
59,378
55,070
50,767
46,533
42,613
38,757
34,220
29,729
25,244
20,821
16,390
16,886
5,410
21,338
15,937
13,081
13,08115,93721,3385,41016,88616,39020,82125,24429,72934,22038,75742,61346,53350,76755,07059,37843,70948,00519,02524,19827,22831,03622,7264,8215,88210,39616,97022,38429,5407,2644,0247,60014,98915,38921,45025,77812,81816,83519,79922,19725,35833,69843,58242,34855,49954,62460,00976,61251,18167,30781,527000
       Short-term Investments 
0
0
0
0
0
0
39,990
39,994
29,999
14,997
14,999
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000014,99914,99729,99939,99439,990000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
132
0
0
1,535
1,504
1,368
2,147
904
31
126
233
57
59
477
72
24
35
35
1,714
23
98
45
41
46
37
38
27
29
28
27
28
28
29
17
17
18
18
18
18
2,121
1,765
1,654
1,323
1,3231,6541,7652,12118181818171729282827282927383746414598231,714353524724775957233126319042,1471,3681,5041,5350013200000000000
       Other Current Assets 
0
0
0
1,725
2,666
5,867
5,326
4,387
4,401
3,331
4,278
3,191
2,655
2,067
1,952
1,882
1,203
1,025
1,218
1,588
898
761
1,050
820
814
545
696
760
759
833
957
650
795
720
757
722
607
457
529
332
583
1,472
1,110
561
802
704
303
1,821
1,745
1,767
1,392
1,848
1,265
966
9661,2651,8481,3921,7671,7451,8213037048025611,1101,4725833325294576077227577207956509578337597606965458148201,0507618981,5881,2181,0251,2031,8821,9522,0672,6553,1914,2783,3314,4014,3875,3265,8672,6661,725000
   > Long-term Assets 
0
0
0
600
786
866
789
763
694
746
649
432
360
312
285
260
236
212
188
164
141
117
95
76
60
46
32
158
151
151
204
200
197
210
206
202
199
185
54
48
45
41
29
25
22
18
27
23
19
15
13
11
207
252
25220711131519232718222529414548541851992022062101972002041511511583246607695117141164188212236260285312360432649746694763789866786600000
       Property Plant Equipment 
0
0
0
463
649
729
652
626
557
609
512
420
348
300
273
248
224
200
176
152
129
105
83
64
48
34
20
9
1
1
54
50
47
60
56
52
49
45
42
38
35
31
28
24
21
17
26
22
18
14
12
10
9
8
89101214182226172124283135384245495256604750541192034486483105129152176200224248273300348420512609557626652729649463000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
242,158
42,544
230,856
28,886
24,253
25,354
25,631
26,611
23,715
24,105
23,162
21,771
12,605
12,823
14,155
18,073
18,106
19,265
15,658
14,880
15,840
15,490
14,288
12,276
12,536
12,877
13,126
12,046
12,100
10,725
12,566
12,992
13,811
11,696
11,385
10,324
9,358
9,135
9,590
10,409
11,063
12,185
11,570
12,521
12,011
12,157
124,206
10,969
56,592
13,063
7,360
7,36013,06356,59210,969124,20612,15712,01112,52111,57012,18511,06310,4099,5909,1359,35810,32411,38511,69613,81112,99212,56610,72512,10012,04613,12612,87712,53612,27614,28815,49015,84014,88015,65819,26518,10618,07314,15512,82312,60521,77123,16224,10523,71526,61125,63125,35424,25328,886230,85642,544242,158000
   > Total Current Liabilities 
0
0
0
25,378
28,230
13,307
14,833
10,338
11,556
11,947
13,042
10,259
10,764
9,935
8,657
7,605
7,642
9,095
9,008
10,160
9,883
9,864
8,989
9,976
10,552
9,976
8,207
8,438
8,409
8,746
8,198
8,292
6,910
8,751
9,290
10,021
7,326
7,499
7,025
6,115
5,948
6,460
7,336
8,046
9,224
8,666
9,674
9,220
9,422
9,910
8,348
11,533
10,401
7,352
7,35210,40111,5338,3489,9109,4229,2209,6748,6669,2248,0467,3366,4605,9486,1157,0257,4997,32610,0219,2908,7516,9108,2928,1988,7468,4098,4388,2079,97610,5529,9768,9899,8649,88310,1609,0089,0957,6427,6058,6579,93510,76410,25913,04211,94711,55610,33814,83313,30728,23025,378000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
5,517
4,243
4,410
4,405
3,710
3,302
5,027
5,385
4,027
3,857
4,185
3,190
3,421
3,296
2,801
4,071
5,323
5,407
5,681
5,436
6,186
7,034
5,949
4,264
4,039
4,334
4,750
4,524
4,271
4,183
5,148
5,725
4,833
3,988
4,290
4,050
2,757
3,122
3,003
3,760
3,860
4,896
5,071
6,148
5,619
6,568
6,174
5,472
8,186
7,656
4,759
4,7597,6568,1865,4726,1746,5685,6196,1485,0714,8963,8603,7603,0033,1222,7574,0504,2903,9884,8335,7255,1484,1834,2714,5244,7504,3344,0394,2645,9497,0346,1865,4365,6815,4075,3234,0712,8013,2963,4213,1904,1853,8574,0275,3855,0273,3023,7104,4054,4104,2435,517000
       Other Current Liabilities 
0
0
0
15,954
20,001
5,388
7,466
5,538
7,591
6,445
7,202
5,759
6,452
5,295
5,012
3,729
3,891
5,839
4,482
4,382
4,021
3,728
3,098
3,335
3,063
3,572
3,488
4,173
3,849
3,770
3,448
3,795
2,501
3,377
3,339
4,962
3,112
2,983
2,749
3,132
2,600
3,231
3,350
3,960
4,102
3,369
3,300
3,375
2,628
3,509
2,650
3,121
2,519
2,593
2,5932,5193,1212,6503,5092,6283,3753,3003,3694,1023,9603,3503,2312,6003,1322,7492,9833,1124,9623,3393,3772,5013,7953,4483,7703,8494,1733,4883,5723,0633,3353,0983,7284,0214,3824,4825,8393,8913,7295,0125,2956,4525,7597,2026,4457,5915,5387,4665,38820,00115,954000
   > Long-term Liabilities 
0
0
0
216,780
14,314
217,549
14,053
13,915
13,798
13,684
13,569
13,456
13,341
13,227
13,114
5,000
5,181
5,060
9,065
7,946
9,382
5,794
5,891
5,864
4,938
4,312
4,069
4,098
4,468
4,380
3,848
3,808
3,815
3,815
3,702
3,790
4,370
3,886
3,299
3,243
3,187
3,130
3,073
3,017
2,961
2,904
2,847
2,791
2,735
114,296
2,621
45,059
2,662
8
82,66245,0592,621114,2962,7352,7912,8472,9042,9613,0173,0733,1303,1873,2433,2993,8864,3703,7903,7023,8153,8153,8083,8484,3804,4684,0984,0694,3124,9385,8645,8915,7949,3827,9469,0655,0605,1815,00013,11413,22713,34113,45613,56913,68413,79813,91514,053217,54914,314216,780000
> Total Stockholder Equity
0
0
0
-158,306
28,215
-172,942
93,831
80,413
63,914
48,519
35,269
22,748
11,758
3,745
3,368
10,010
5,989
1,217
9,185
4,297
-3,541
-388
-6,908
-11,691
-7,705
15,915
10,860
5,387
-1,536
-4,546
-6,041
11,574
21,348
15,633
12,215
6,175
37,153
32,993
49,666
46,120
42,287
38,484
33,371
28,309
22,876
18,898
14,517
10,672
6,015
-105,520
-2,033
-31,630
6,000
8,262
8,2626,000-31,630-2,033-105,5206,01510,67214,51718,89822,87628,30933,37138,48442,28746,12049,66632,99337,1536,17512,21515,63321,34811,574-6,041-4,546-1,5365,38710,86015,915-7,705-11,691-6,908-388-3,5414,2979,1851,2175,98910,0103,3683,74511,75822,74835,26948,51963,91480,41393,831-172,94228,215-158,306000
   Common Stock
0
0
0
26
154
26
214
215
217
217
0
217
217
217
237
25
274
27
68
68
68
99
99
8
194
851
57
57
59
60
82
1,112
1,674
1,742
1,845
124
2,367
158
209
209
209
209
209
209
210
210
210
210
211
253
30
36
50
71
715036302532112102102102102092092092092092091582,3671241,8451,7421,6741,112826059575785119489999686868272742523721721721702172172152142615426000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
7
5
-18
1
0
0
-8
-13
-43
-14
-18
-22
-16
-19
-17
-31
-26
-10
-1
3
11
-5
-7
-12
-18
-14
-27
-18
-24
-17
-2
14
-2
2
-6
-14
-21
-41
-61
-33
-27
-28
-30
-23
-30
-33
-33
-42
-19
9
9-19-42-33-33-30-23-30-28-27-33-61-41-21-14-62-214-2-17-24-18-27-14-18-12-7-5113-1-10-26-31-17-19-16-22-18-14-43-13-8001-18570000
   Capital Surplus 000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,021
211,252
22,787
309,916
311,093
313,272
314,630
316,483
317,122
318,505
319,418
324,898
328,564
331,528
332,387
341,911
342,484
342,982
348,672
349,103
350,614
359,496
385,966
387,055
387,238
387,919
388,465
391,556
413,879
428,189
429,794
432,499
434,593
468,059
470,335
490,418
490,644
490,940
491,181
491,486
491,816
492,151
492,424
492,784
493,116
493,448
505,017
617,202
617,530
633,633
636,761
636,761633,633617,530617,202505,017493,448493,116492,784492,424492,151491,816491,486491,181490,940490,644490,418470,335468,059434,593432,499429,794428,189413,879391,556388,465387,919387,238387,055385,966359,496350,614349,103348,672342,982342,484341,911332,387331,528328,564324,898319,418318,505317,122316,483314,630313,272311,093309,91622,787211,25210,021000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue226
Cost of Revenue-12
Gross Profit214214
 
Operating Income (+$)
Gross Profit214
Operating Expense-49,562
Operating Income-49,348-49,348
 
Operating Expense (+$)
Research Development130,311
Selling General Administrative12,289
Selling And Marketing Expenses0
Operating Expense49,562142,600
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-49,348
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-166,52367,827
EBIT - interestExpense = -166,523
-54,674
-54,674
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-166,523-166,523
Earnings Before Interest and Taxes (EBITDA)-166,511
 
After tax Income (+$)
Income Before Tax-166,523
Tax Provision-0
Net Income From Continuing Ops-166,523-166,523
Net Income-54,674
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses49,574
Total Other Income/Expenses Net-117,1750
 

Technical Analysis of Traws Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Traws Pharma Inc. The general trend of Traws Pharma Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Traws Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Traws Pharma Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Traws Pharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.52 < 2.58 < 2.63.

The bearish price targets are: 2.15 > 1.34 > 1.26.

Know someone who trades $TRAW? Share this with them.πŸ‘‡

Traws Pharma Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Traws Pharma Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Traws Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Traws Pharma Inc. The current macd is 0.08523271.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Traws Pharma Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Traws Pharma Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Traws Pharma Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Traws Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartTraws Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Traws Pharma Inc. The current adx is 43.34.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Traws Pharma Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Traws Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Traws Pharma Inc. The current sar is 1.72.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Traws Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Traws Pharma Inc. The current rsi is 70.41. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Traws Pharma Inc Daily Relative Strength Index (RSI) ChartTraws Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Traws Pharma Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Traws Pharma Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Traws Pharma Inc Daily Stochastic Oscillator ChartTraws Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Traws Pharma Inc. The current cci is 163.70.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Traws Pharma Inc Daily Commodity Channel Index (CCI) ChartTraws Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Traws Pharma Inc. The current cmo is 47.86.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Traws Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartTraws Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Traws Pharma Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Traws Pharma Inc Daily Williams %R ChartTraws Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Traws Pharma Inc.

Traws Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Traws Pharma Inc. The current atr is 0.14299848.

Traws Pharma Inc Daily Average True Range (ATR) ChartTraws Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Traws Pharma Inc. The current obv is 83,578,042.

Traws Pharma Inc Daily On-Balance Volume (OBV) ChartTraws Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Traws Pharma Inc. The current mfi is 54.45.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Traws Pharma Inc Daily Money Flow Index (MFI) ChartTraws Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Traws Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-10BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Traws Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Traws Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.411
Ma 20Greater thanMa 501.928
Ma 50Greater thanMa 1001.677
Ma 100Greater thanMa 2001.594
OpenGreater thanClose1.830
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Traws Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Traws Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Traws Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Traws Pharma Inc

I send you an email if I find something interesting about Traws Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Traws Pharma Inc.

Receive notifications about Traws Pharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.